Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial evaluating the combination of the company's drug candidates lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
Data from the MYTHIC trial showed that Lunresertib, when combined with Camonsertib, resulted in promising response rates, including a 25.9 percent overall response rate (ORR) in endometrial cancer and a 37.5 percent ORR in platinum-resistant ovarian cancer.
The company plans to initiate a registrational Phase 3 Lunre+Camo trial in endometrial cancer in 2025.
The company showcased positive updated safety and tolerability data from the MYTHIC trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024.
The data revealed the benefits of an individualized dosing schedule for managing anemia. Importantly, dose optimization reduced Grade 3 anemia to 22.6 percent, down from 51.4 percent, without any instances of thrombocytopenia or serious neutropenia.
Repare also provided insight into its ongoing research with Camonsertib (RP-3500), a promising ATR inhibitor, currently being studied in non-small cell lung cancer (NSCLC) as a monotherapy and in combination with radiation therapy for tumors harboring ATM mutations.
As of September 30, 2024, Repare had cash, cash equivalents, and marketable securities totaling $179.4 million. The company expects this capital to fund its operations into the second half of 2026.
Repare is focused on advancing its clinical-stage oncology programs, following a strategic reprioritization in August 2024, which included a workforce reduction of approximately 25 percent, primarily from its preclinical group.
RPTX closed Thursday's trading at $3.97, up 10.28%. In premarket trading today, the stock is down 37.27% at $2.49.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.